Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, describes the management of patients with B-cell lymphomas relapsing following treatment with CD19-targeted chimeric antigen receptor (CAR) T-cells, commenting on the role of allogeneic hematopoietic stem cell transplantation. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.